NuCana to Present Two Abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2020
May 15, 2020 07:00 ET
|
NuCana plc
Non-Clinical Findings Suggest that Acelarin and NUC-3373 May Induce an Immune Response Against Cancer Cells Acelarin (NUC-1031) Releases DAMPs and Upregulates PD-L1 Expression in Lung Cancer Cells ...
NuCana Announces Re-Opening of Global Phase III Study of Acelarin Plus Cisplatin in Patients with Biliary Tract Cancer (NuTide:121)
May 05, 2020 16:01 ET
|
NuCana plc
EDINBURGH, U.K., May 05, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced it has re-commenced enrollment of new patients in NuTide:121, its ongoing global Phase III study of Acelarin...
NuCana Provides Update on Impact of COVID-19 on Clinical Studies
April 02, 2020 16:01 ET
|
NuCana plc
EDINBURGH, United Kingdom, April 02, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) has been closely monitoring the potential impact of the COVID-19 pandemic on its operations and announced...
NuCana Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Business Update
March 10, 2020 16:02 ET
|
NuCana plc
First Patients Dosed in Global Phase III Biliary Tract Cancer Study (NuTide:121) with Potential for Accelerated Approval Filing Numerous Clinical Data Announcements Expected in 2020 Cash and Cash...
NuCana Reports Preliminary Data from Phase II Study of Single-Agent Acelarin (NUC-1031) in Patients with Platinum-Resistant Ovarian Cancer
March 10, 2020 16:01 ET
|
NuCana plc
Confirmed Complete Response and Two Partial Responses Achieved in Heavily Pre-treated Population Patients had Median of Five Prior Lines of Therapy EDINBURGH, United Kingdom, March 10, 2020 (GLOBE...
NuCana Receives Positive Opinion for Orphan Drug Designation in the European Union for Acelarin (NUC-1031) for the Treatment of Patients with Biliary Tract Cancer
March 04, 2020 07:00 ET
|
NuCana plc
EDINBURGH, United Kingdom, March 04, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) has issued...
NuCana to Present at the Cowen and Company 40th Annual Health Care Conference
February 25, 2020 07:00 ET
|
NuCana plc
EDINBURGH, United Kingdom, Feb. 25, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will...
NuCana Announces First Patients Dosed in Both US and Europe in Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer
January 27, 2020 07:00 ET
|
NuCana plc
Global NuTide:121 Study Is Enrolling up to 828 Patients and Comparing Acelarin plus Cisplatin to Gemcitabine plus Cisplatin NuTide:121 Trials-in-Progress Poster Presented at ASCO-GI SAN FRANCISCO,...
NuCana to Participate in the Piper Jaffray 31st Annual Healthcare Conference
November 26, 2019 07:00 ET
|
NuCana plc
EDINBURGH, United Kingdom, Nov. 26, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Don Munoz, Chief Financial Officer, will host one-on-one meetings at the Piper Jaffray...
NuCana to Present at the Jefferies 2019 London Healthcare Conference
November 14, 2019 07:00 ET
|
NuCana plc
EDINBURGH, United Kingdom, Nov. 14, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will...